SERIES A WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Foresight Autonomous Holdings Ltd.Security Agreement • March 12th, 2025 • Foresight Autonomous Holdings Ltd. • Services-prepackaged software
Contract Type FiledMarch 12th, 2025 Company IndustryTHIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the later of June 30, 2025 or 90 Trading Days following the Effective Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Foresight Autonomous Holdings Ltd., an Israeli company (the “Company”), up to the amount of ordinary shares, no par value per share, of the Company (the “Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”) calculated in accordance with the provisions of Section 2(a) below and represented by American Depositary Shares (“ADSs”), each ADS representing thirty (30) Ordinary Shares (the ADSs issuab
SERIES B WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES Foresight Autonomous Holdings Ltd.Security Agreement • March 12th, 2025 • Foresight Autonomous Holdings Ltd. • Services-prepackaged software
Contract Type FiledMarch 12th, 2025 Company IndustryTHIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on March 10, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Foresight Autonomous Holdings Ltd., an Israeli company (the “Company”), up to ______ ordinary shares, no par value per share, of the Company (the “Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”) represented by __________ American Depositary Shares (“ADSs”), each ADS representing thirty (30) Ordinary Shares (the ADSs issuable hereunder, the “Warrant ADSs”). The purchase price of one Warrant ADS shall be equal c
Warrant No. A-[•] Initial Exercise Date: [•], 2025 Issuance Date: [•], 2025Security Agreement • March 3rd, 2025 • Akari Therapeutics PLC • Pharmaceutical preparations
Contract Type FiledMarch 3rd, 2025 Company IndustryTHIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [•], 2025 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [•], 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Akari Therapeutics, Plc., a public company with limited liability incorporated under the laws of England and Wales (the “Company”), up to [•] Ordinary Shares (the “Warrant Shares”) represented by [•]American Depositary Shares (“ ADSs”), as subject to adjustment hereunder (the “Warrant ADSs”). The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b).
PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES AKARI THERAPEUTICS, PLCSecurity Agreement • March 3rd, 2025 • Akari Therapeutics PLC • Pharmaceutical preparations
Contract Type FiledMarch 3rd, 2025 Company IndustryTHIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, [•] or [its] assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Company”), up to [•] ordinary shares, par value $0.0001 per share, of the Company (the “Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”) represented by [•] American Depository Shares (“ADSs”, each ADS representing 2,000 Ordinary Shares, and the ADSs issuable hereunder, the “Warrant ADSs”). The purchase price of one Warrant ADS under this Warrant shall be equal to the Exercise Price, as
PREFUNDED ADS PURCHASE WARRANT Steakholder Foods Ltd.Security Agreement • February 28th, 2025 • Steakholder Foods Ltd. • Food and kindred products • Delaware
Contract Type FiledFebruary 28th, 2025 Company Industry JurisdictionTHIS PREFUNDED ADS PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Alumni Capital LP or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Steakholder Foods Ltd., an Israeli corporation (the “Company”), up to 792,368 ADSs (as subject to adjustment hereunder, the “Warrant ADSs”). The purchase price of one ADS under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES KAZIA THERAPEUTICS LIMITEDSecurity Agreement • January 13th, 2025 • Kazia Therapeutics LTD • Pharmaceutical preparations
Contract Type FiledJanuary 13th, 2025 Company IndustryTHIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _________________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [___], 20251 (the “Initial Exercise Date”) on or prior to 5:00 p.m. (New York City time) on [___], 20302 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Kazia Therapeutics Limited, a company incorporated under the laws of Australia (the “Company”), up to _________ ordinary shares, no par value per share (the “Ordinary Shares”), of the Company (the “Warrant Shares”) represented by _________ American Depositary Shares (each, an “ADS” and, collectively, the “ADSs” and the ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be e
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES KAZIA THERAPEUTICS LIMITEDSecurity Agreement • January 13th, 2025 • Kazia Therapeutics LTD • Pharmaceutical preparations
Contract Type FiledJanuary 13th, 2025 Company IndustryTHIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _________________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) on or prior to 5:00 p.m. (New York City time) on [_____________]1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Kazia Therapeutics Limited, a company incorporated under the laws of Australia (the “Company”), up to _________ ordinary shares, no par value per share (the “Ordinary Shares”), of the Company (the “Warrant Shares”) represented by _________ American Depositary Shares (each, an “ADS” and, collectively, the “ADSs” and the ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to t
AMENDED AND RESTATED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTDSecurity Agreement • April 4th, 2023 • Addex Therapeutics Ltd. • Pharmaceutical preparations
Contract Type FiledApril 4th, 2023 Company IndustryTHIS AMENDED AND RESTATED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July 5, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 5, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Addex Therapeutics Ltd, a Swiss limited company established and existing under the laws of Switzerland (the “Company”), up to 9,230,772 Ordinary Shares, par value CHF 0.01 per share (the “Warrant Shares”), represented by 1,538,462 ADSs (such ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. This Amended and Restated Warrant is issued pursuant to that certain Letter Agreement, dated as of April 3
AMENDED AND RESTATED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTDSecurity Agreement • April 4th, 2023 • Addex Therapeutics Ltd. • Pharmaceutical preparations
Contract Type FiledApril 4th, 2023 Company IndustryTHIS AMENDED AND RESTATED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July 5, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 5, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Addex Therapeutics Ltd, a Swiss limited company established and existing under the laws of Switzerland (the “Company”), up to 15,000,000 Ordinary Shares, par value CHF 0.01 per share (the “Warrant Shares”), represented by 2,500,000 ADSs (such ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. This Amended and Restated Warrant is issued pursuant to that certain Letter Agreement, dated as of April
PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTDSecurity Agreement • April 4th, 2023 • Addex Therapeutics Ltd. • Pharmaceutical preparations
Contract Type FiledApril 4th, 2023 Company IndustryTHIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June 4, 2023 (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), but not thereafter, to subscribe for and purchase from Addex Therapeutics Ltd, a Swiss limited company established and existing under the laws of Switzerland (the “Company”), up to 23,578,950 Ordinary Shares, par value CHF 0.01 per share (the “Warrant Shares”), represented by 3,929,825 ADSs (such ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b)
PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES midatech pharma plcSecurity Agreement • February 9th, 2023 • Midatech Pharma PLC • Pharmaceutical preparations
Contract Type FiledFebruary 9th, 2023 Company IndustryTHIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _________, 2023 (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Midatech Pharma PLC, a public limited company organized under the laws of England and Wales (the “Company”), up to ______ Ordinary Shares (the “Warrant Shares”) represented by _________ American Depositary Shares (“ADSs”), as subject to adjustment hereunder (the “Warrant ADSs”). The purchase price of one Warrant ADS under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). In addition to the other adjustments provided herein, on the sixth (6th) Trading Day following each
PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTDSecurity Agreement • July 26th, 2022 • Addex Therapeutics Ltd. • Pharmaceutical preparations
Contract Type FiledJuly 26th, 2022 Company IndustryTHIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Warrant”) certifies that, for value received,________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _____________ (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), but not thereafter, to subscribe for and purchase from Addex Therapeutics Ltd, a Swiss limited company established and existing under the laws of Switzerland (the “Company”), up to __________________ Ordinary Shares, par value CHF 1.00 per share (the “Warrant Shares”), represented by _________________ ADSs (such ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b)
FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTDSecurity Agreement • December 20th, 2021 • Addex Therapeutics Ltd. • Pharmaceutical preparations
Contract Type FiledDecember 20th, 2021 Company IndustryTHIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [December ____], 20212 (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), but not thereafter, to subscribe for and purchase from Addex Therapeutics Ltd, a Swiss limited company established and existing under the laws of Switzerland (the “Company”), up to ______ Ordinary Shares, par value CHF 1.00 per share (the “Warrant Shares”), represented by ______ ADSs (such ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b)
AMERICAN DEPOSITARY SHARES PURCHASE WARRANT ANCHIANO THERAPEUTICS LTD.Security Agreement • March 17th, 2021 • Anchiano Therapeutics Ltd. • Pharmaceutical preparations • New York
Contract Type FiledMarch 17th, 2021 Company Industry JurisdictionTHIS AMERICAN DEPOSITARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [___], 2021 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [___], 2026 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Anchiano Therapeutics Ltd., an Israeli public company incorporated under the laws of Israel (the “Company”), up to ______ American Depositary Shares (“ADSs”), each ADS representing five (5) ordinary shares, no par value, of the Company (the “Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”) (the ADSs issuable hereunder, the “Warrant ADSs”). The purchase price of one ADS under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
AMERICAN DEPOSITARY SHARES PURCHASE WARRANT Therapix Biosciences Ltd.Security Agreement • July 1st, 2020 • Therapix Biosciences Ltd. • Pharmaceutical preparations • New York
Contract Type FiledJuly 1st, 2020 Company Industry JurisdictionTHIS AMERICAN DEPOSITARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after January 1, 2021 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 2, 2026 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Therapix Biosciences Ltd., an Israeli public company incorporated under the laws of Israel (the “Company”), up to ______ American Depositary Shares (“ADSs”), each ADS representing forty (40) ordinary shares, NIS 0.10 par value per Ordinary Share, of the Company (the “Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”) (the ADSs issuable hereunder, the “Warrant ADSs”). The purchase price of one ADS under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES midatech pharma plcSecurity Agreement • May 20th, 2020 • Midatech Pharma PLC • Pharmaceutical preparations
Contract Type FiledMay 20th, 2020 Company IndustryTHIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May 18, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Midatech Pharma PLC, a public limited company organized under the laws of England and Wales (the “Company”), up to ______ Ordinary Shares (the “Warrant Shares”) represented by American Depositary Shares (“ADSs”), as subject to adjustment hereunder (the “Warrant ADSs”). The purchase price of one Warrant ADS under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain engagement letter, d
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES midatech pharma plcSecurity Agreement • October 25th, 2019 • Midatech Pharma PLC • Pharmaceutical preparations
Contract Type FiledOctober 25th, 2019 Company IndustryTHIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the earlier of (x) a time when there is an effective registration statement to cover the issuance of the Warrant ADSs, and such Warrant ADSs or Warrant Shares may be issued free of all legends, each as evidenced by an opinion of counsel reasonably satisfactory to the Depositary delivered to the Depositary, or (y) the entry into a restricted issuance agreement (the “Restricted Issuance Agreement”) by and among the Company , the Depositary and all holders and beneficial owners of restricted American Depositary Shares evidenced by restricted American Depositary Receipts to be issued thereunder, which such Restricted Issuance Agreement shall be in form and substance satisfactory